DMAC Share Price Performance
US$6.94
1.78 (34.66%)
55.3% undervalued intrinsic discount
US$15.50
Fair Value
Price US$6.94
AnalystConsensusTarget US$15.50
AnalystHighTarget US$25.00
Fair ValueUS$15.50
Share Pricen/a
DiaMedica Therapeutics Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
DMAC Community Narratives
AN
Fair Value
·Fair Value US$15.5 55.3% undervalued intrinsic discount
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$25 72.3% undervalued intrinsic discount
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Read more
AN
US$25
72.3% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
330.89x
Price in 2029
US$0
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Read more
AN
US$15.5
55.3% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
968.89x
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Fair Value: US$25 72.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Fair Value: US$15.5 55.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DiaMedica Therapeutics Inc. Key Details
About DMAC
- Founded
- 2000
- Employees
- 35
- CEO
- WebsiteView website
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
